Peptide receptor radionuclide therapy ( Lu-DOTATATE) causes DNA strand breaks and has been validated for well-differentiated neuroendocrine tumor treatment. Poly-(ADP-ribose)-polymerase inhibitors have also been used for malignant tumors with deficient DNA repair. We aimed to determine whether the poly-(ADP-ribose)-polymerase inhibitor fluzoparib could enhance the anti-tumor effects of Lu-DOTATATE in neuroendocrine tumor cells and xenografts.
View Article and Find Full Text PDFAlthough neuroendocrine tumours (NETs) are intensively studied, their diagnosis and consequently personalised therapy management is still puzzling due to their tumoral heterogeneity. In their theragnosis algorithm, receptor somatostatin scintigraphy takes the central place, the diagnosis receptor somatostatin analogue (RSA) choice depending on laboratory experience and accessibility. However, in all cases, the results depend decisively on correct radiotracer tumoral uptake quantification, where unfortunately there are still unrevealed clues and lack of standardization.
View Article and Find Full Text PDFGastrin-secreting tumors, hypergastrinemia and severe ulcer disease form the trademarks of Zollinger-Ellison syndrome (ZES). We report a case of gastrinoma, in a patient who was misdiagnosed for almost five years. The case emphsizes the the special role of functional imaging in the personalized approach to the patient with suggestive symptomatology for NETs.
View Article and Find Full Text PDFActa Endocrinol (Buchar)
January 2020
Context: The variety of tumor-seeking radiopharmaceuticals, which are currently in clinical use, may have a potential role as imaging agents for adrenal gland tumors, due to physiological characteristics of this organ.
Objective: The purpose of this study was to evaluate the diagnostic potential of Tc-HYNIC-TOC, Tc(V)-DMSA, and Tc-MIBI in the assessment of adrenal tumors, by correlating with imaging findings and histopathologic results.
Design: The research is designed as a cross-sectional prospective study.